伊曲康唑与氟康唑治疗兔隐球菌性脑膜炎和念珠菌性肾盂肾炎的比较。
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.
作者信息
Perfect J R, Savani D V, Durack D T
出版信息
Antimicrob Agents Chemother. 1986 Apr;29(4):579-83. doi: 10.1128/AAC.29.4.579.
Abstract
Itraconazole and fluconazole, two new triazoles, were examined for their antifungal activity in rabbits. Fluconazole easily crossed the blood-cerebrospinal fluid barrier, and active drug was eliminated in high concentrations in the urine. On the other hand, itraconazole did not cross the blood-cerebrospinal fluid barrier in measurable amounts, and urine concentrations were variable. Despite differences in pharmacokinetics at the site of infection, both agents were equally effective in treating cryptococcal meningitis and candida pyelonephritis in animals. By using a ketoconazole-resistant strain of Candida albicans, we showed that there was cross-resistance in vivo between these two new triazole compounds.
摘要
对两种新型三唑类药物伊曲康唑和氟康唑在兔体内的抗真菌活性进行了研究。氟康唑易于穿过血脑脊髓液屏障，活性药物在尿液中以高浓度排出。另一方面，伊曲康唑未能以可测量的量穿过血脑脊髓液屏障，尿液浓度也各不相同。尽管在感染部位的药代动力学存在差异，但这两种药物在治疗动物隐球菌性脑膜炎和念珠菌性肾盂肾炎方面同样有效。通过使用对酮康唑耐药的白色念珠菌菌株，我们表明这两种新型三唑类化合物在体内存在交叉耐药性。
相似文献
1
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.伊曲康唑与氟康唑治疗兔隐球菌性脑膜炎和念珠菌性肾盂肾炎的比较。
Antimicrob Agents Chemother. 1986 Apr;29(4):579-83. doi: 10.1128/AAC.29.4.579.
2
The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis.BAY R3783的药代动力学及其在治疗实验性隐球菌性脑膜炎中的疗效。
J Antimicrob Chemother. 1990 Sep;26(3):387-97. doi: 10.1093/jac/26.3.387.
3
Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.用SCH39304治疗实验性隐球菌性脑膜炎和播散性念珠菌病。
Antimicrob Agents Chemother. 1989 Oct;33(10):1735-40. doi: 10.1128/AAC.33.10.1735.
4
Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis.新型唑类化合物在眼部的渗透及对实验性念珠菌性眼内炎的疗效
Antimicrob Agents Chemother. 1987 Jan;31(1):6-10. doi: 10.1128/AAC.31.1.6.
5
Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.在浅表和全身性念珠菌病、脑膜隐球菌病及肺曲霉病的啮齿动物模型中对Bay R 3783进行评估。
Antimicrob Agents Chemother. 1990 Mar;34(3):448-54. doi: 10.1128/AAC.34.3.448.
6
Treatment of cryptococcal meningitis in mice with fluconazole.用氟康唑治疗小鼠隐球菌性脑膜炎。
J Antimicrob Chemother. 1986 Aug;18(2):261-70. doi: 10.1093/jac/18.2.261.
7
Azole antifungal agents: emphasis on new triazoles.唑类抗真菌药物：重点介绍新型三唑类药物。
Antimicrob Agents Chemother. 1988 Jan;32(1):1-8. doi: 10.1128/AAC.32.1.1.
8
Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.氟康唑（UK 49,858）和酮康唑对酮康唑敏感及耐药白色念珠菌的活性。
Antimicrob Agents Chemother. 1988 Feb;32(2):209-12. doi: 10.1128/AAC.32.2.209.
9
Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice.两性霉素B、氟康唑和伊曲康唑对正常和中性粒细胞减少小鼠系统性白色念珠菌感染的疗效比较。
Antimicrob Agents Chemother. 1989 Feb;33(2):147-51. doi: 10.1128/AAC.33.2.147.
10
Itraconazole therapy for cryptococcal meningitis and cryptococcosis.伊曲康唑治疗隐球菌性脑膜炎和隐球菌病。
Arch Intern Med. 1989 Oct;149(10):2301-8.
引用本文的文献
1
Advancing cryptococcal treatment: The role of nanoparticles in mitigating antifungal resistance.推进隐球菌治疗：纳米颗粒在减轻抗真菌耐药性中的作用。
Curr Res Microb Sci. 2024 Nov 22;8:100323. doi: 10.1016/j.crmicr.2024.100323. eCollection 2025.
2
Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis.APX2039 在兔隐球菌性脑膜炎模型中的疗效。
mBio. 2022 Dec 20;13(6):e0234722. doi: 10.1128/mbio.02347-22. Epub 2022 Oct 12.
3
CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).细胞色素P450 51（CYP51）是治疗原发性阿米巴脑膜脑炎（PAM）的关键药物靶点。
PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006104. doi: 10.1371/journal.pntd.0006104. eCollection 2017 Dec.
4
Antifungal pharmacokinetics and pharmacodynamics.抗真菌药物的药代动力学与药效学
Cold Spring Harb Perspect Med. 2014 Nov 10;5(5):a019653. doi: 10.1101/cshperspect.a019653.
5
Pediatric seizure disorders in dogs and cats.犬猫的小儿癫痫症
Vet Clin North Am Small Anim Pract. 2014 Mar;44(2):275-301. doi: 10.1016/j.cvsm.2013.10.004. Epub 2013 Dec 5.
6
Tissue penetration of antifungal agents.抗真菌药物的组织穿透性。
Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13.
7
Transcriptomic analysis of Ustilago maydis infecting Arabidopsis reveals important aspects of the fungus pathogenic mechanisms.转录组分析显示玉米黑粉菌感染拟南芥揭示了真菌致病机制的重要方面。
Plant Signal Behav. 2013 Aug;8(8). doi: 10.4161/psb.25059. Epub 2013 Jun 11.
8
Reflections on the approach to treatment of a mycologic disaster.关于真菌病灾难治疗方法的思考
Antimicrob Agents Chemother. 2013 Apr;57(4):1567-72. doi: 10.1128/AAC.02242-12. Epub 2013 Feb 5.
9
Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum.采用等度高效液相色谱法并结合紫外检测，同时测定人血清中伏立康唑、伊曲康唑及其羟基代谢物的含量。
Antimicrob Agents Chemother. 2005 Aug;49(8):3569-71. doi: 10.1128/AAC.49.8.3569-3571.2005.
10
In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.新型三唑类药物阿巴康唑对新型隐球菌的体内外疗效
Antimicrob Agents Chemother. 2004 Feb;48(2):384-7. doi: 10.1128/AAC.48.2.384-387.2004.
本文引用的文献
1
Chronic cryptococcal meningitis: a new experimental model in rabbits.慢性隐球菌性脑膜炎：家兔新实验模型
Am J Pathol. 1980 Oct;101(1):177-94.
2
Strategies in the treatment of systemic fungal infections.系统性真菌感染的治疗策略。
N Engl J Med. 1980 Jan 17;302(3):145-55. doi: 10.1056/NEJM198001173020304.
3
Urinary tract infections due to Candida albicans.白色念珠菌引起的尿路感染
Rev Infect Dis. 1982 Nov-Dec;4(6):1107-18. doi: 10.1093/clinids/4.6.1107.
4
Cryptococcemia.隐球菌血症
Medicine (Baltimore). 1983 Mar;62(2):98-109. doi: 10.1097/00005792-198303000-00003.
5
Azole resistance in Candida albicans.白色念珠菌中的唑类耐药性。
Sabouraudia. 1984;22(1):53-63.
6
Antifungal agents useful in therapy of systemic fungal infections.可用于全身性真菌感染治疗的抗真菌药物。
Annu Rev Pharmacol Toxicol. 1983;23:303-30. doi: 10.1146/annurev.pa.23.040183.001511.
7
Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis.酮康唑治疗进行性球孢子菌病三种主要表现形式的经验。
Am J Med. 1983 Jan 24;74(1B):58-63. doi: 10.1016/0002-9343(83)90515-6.
8
Treatment of paracoccidioidomycosis with ketoconazole: a three-year experience.酮康唑治疗副球孢子菌病：三年经验
Am J Med. 1983 Jan 24;74(1B):48-52. doi: 10.1016/0002-9343(83)90513-2.
9
Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients.酮康唑治疗慢性黏膜皮肤念珠菌病的长期疗效：21例患者的经验
Am J Med. 1983 Jan 24;74(1B):23-9. doi: 10.1016/0002-9343(83)90511-9.
10
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.酮康唑治疗系统性真菌病：52例患者的毒性及临床反应重点。美国国立过敏和传染病研究所抗真菌协作研究。
Ann Intern Med. 1983 Jan;98(1):13-20. doi: 10.7326/0003-4819-98-1-13.
Zotero 插件